Navigation Links
MaxCyte to Present at the BIO CEO & Investor Conference
Date:2/6/2008

GAITHERSBURG, Md., Feb. 6 /PRNewswire/ -- MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical, non-viral cell loading systems, announces Douglas Doerfler, President & CEO, will be presenting at the BIO CEO & Investor Conference in New York, Waldorf=Astoria, on Monday, February 11, 2008 at 11:45AM.

Mr. Doerfler will provide a brief corporate overview and discuss the company's preclinical and clinical product portfolio, partnering candidates, and enabling technology for therapeutic development and biotherapeutic manufacturing.

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary, non-viral, ex vivo cell loading technology provide safety, scalability and reproducibility capabilities which are fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). MaxCyte has recently partnered with Medinet (JP) to commercialize a cell based therapy to be launched in 2008. In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER).

For more information, visit http://www.maxcyte.com.


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. MaxCyte to Present at the Phacilitate Cell and Gene Therapy Forum 2008
2. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
3. HMS Holdings Corp. to Present at 2008 UBS Global Healthcare Services Conference
4. West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference
5. Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona
6. Vical to Present at BIO CEO and Investor Conference
7. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
8. NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
9. DURECT to Present at BIO CEO Investor Conference 2008
10. BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation
11. Bush Budget Represents Double Whammy Hit on U.S. Seniors Medicare-Financed Nursing Facility Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... ... In Madeira Beach Florida, a small town with 4,300 residents on a ... Madeira Beach United, to oppose two development projects undertaken by their city government that ... rise urban environment. , According to the Tampa Bay Times on May ...
(Date:5/26/2016)... ... May 26, 2016 , ... HealthPostures, ergonomics designer and ... , furniture that may support women during pregnancy. Potential benefits of using the Stance ... rest and comfort and healthier levels of sitting and standing. , Need for the ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Association/American Stroke Association's Get With The Guidelines®-Stroke Gold Plus Achievement Award with ... second for Memorial Healthcare System, recognizes its commitment to emergency stroke care ...
(Date:5/25/2016)... ... May 25, 2016 , ... Serenity Recovery, a ... video highlighting one of the many supplemental program options offered at their rehabilitation ... 5 th Degree Black Belt in the Shorin-ryu style of Karate that originated ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Program (KOHP), a $500,000 two-year pilot initiative to improve oral health-related awareness, education, ... professional development for health care providers and promote best practices in 10 New ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016  NxStage Medical, Inc. (Nasdaq: NXTM ... renal care, today announced that Jeffrey H. Burbank ... following schedule of investor conferences. Where applicable, a webcast ... http://ir.nxstage.com/ .   ... NY           Friday, June 10, 2016 1:30 p.m. ET ...
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice ... officer, today. In his new role, Marziani will lead the company,s business development and ... to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
Breaking Medicine Technology: